Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · August 13, 2022

Seladelpar Reduces Alkaline Phosphatase Levels in Patients With Primary Biliary Cholangitis

Journal of Hepatology


Additional Info

Journal of Hepatology
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
J. Hepatol. 2022 Aug 01;77(2)353-364, CL Bowlus, MR Galambos, RJ Aspinall, GM Hirschfield, DEJ Jones, Y Dörffel, SC Gordon, SA Harrison, AE Kremer, MJ Mayo, PJ Thuluvath, C Levy, MG Swain, GW Neff, DA Sheridan, CM Stanca, CP Berg, A Goel, ML Shiffman, JM Vierling, P Boudes, A Steinberg, YJ Choi, CA McWherter

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading